Navigation Links
Structural biology spin-out tackles major diseases
Date:8/7/2008

A spin out company from basic structural biology, Asterion Ltd., has led to new technology that provides a way of creating therapeutic proteins to tackle major diseases such as cancer, diabetes and infertility. The research was carried out at the University of Sheffield in laboratories supported by the Biotechnology and Biological Sciences Research Council (BBSRC). This work is reported in the current edition of BBSRC Business, the quarterly research highlights magazine of the Biotechnology and Biological Sciences Research Council.

Professor Richard Ross, Chief Scientific Officer of Asterion Ltd., said: "A big challenge for biological therapeutics is that they are broken down rapidly in the body. The technology developed by Asterion Ltd. is based on basic structural biology work that has provided us with the knowledge necessary to develop longer acting drugs. This is a major advantage for patients, as it means monthly injections rather than daily injections."

Professor Ross, along with fellow founding directors Professors Pete Artymiuk and Jon Sayers have shown that it is possible to engineer proteins that can intervene when there is a deficiency in hormones. Their initial experiments involved fusing different elements of hormone and receptor in order to treat a growth disorders such as short stature (a deficiency in growth hormone).

Professor Ross continued: "Our patented and versatile therapeutic platform technology ProFuse TM, could also tackle major diseases such as some cancers, anaemia, infertility and diabetes. Under normal circumstances hormones of the type known as cytokine hormones - growth hormone for example - circulate in the blood and are bound to proteins that prevent them from being degraded. The basic structural biology work we have done in the past means that we can see the interaction between the hormone and the binding protein in exquisite detail. Our understanding of this structural information means that we can rationally design drugs that consist of this pairing of hormone and binding protein that still allows them to activate the cell surface receptor. In this situation, the hormone portion of the drug is better protected in the circulation from degradation and so it has a much longer effective life in the body."

This system of drug design has been developed by Asterion Ltd. into a patented and versatile therapeutic platform technology called ProFuse. Using this technology it will be possible to make other useful pairings between therapeutic hormones and protective receptor domains (the binding proteins) that could be used to tackle major diseases such as some cancers, anaemia, infertility and diabetes.


'/>"/>

Contact: Nancy Mendoza
press.office@bbsrc.ac.uk
44-017-934-13355
Biotechnology and Biological Sciences Research Council
Source:Eurekalert

Related biology news :

1. Researchers discover the structural alphabet of RNA
2. Cold Spring Harbor Protocols highlights gene silencing, cancer cell biology methods
3. Tips from the Journals of the American Society for Microbiology
4. American Society for Microbiology honors Victor de Lorenzo
5. American Society for Microbiology honors Katharine R. Clapham
6. American Society for Microbiology honors Stephen C. Edberg
7. American Society for Microbiology honors Steven A. Rosenberg
8. American Society for Microbiology honors Vickie S. Baselski
9. American Society for Microbiology honors Mary Ann Moran
10. American Society for Microbiology honors Regina S. Van Brakle
11. American Society for Microbiology honors Marvin Whiteley
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... , ... October 11, 2017 , ... ... the implantation and pregnancy rates in frozen and fresh in vitro fertilization ... progesterone and maternal age to IVF success. , After comparing the results from ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks ... Strategy, will speak at the TMA 2017 Annual Meeting , October ... trends in the residential home security market and how smart safety and ... Parks ... "The residential ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon ... awards honoring scientists who have made outstanding contributions to analytical chemistry ... Pittcon 2018, the world’s leading conference and exposition for laboratory science, which will ...
Breaking Biology Technology: